Modern Myelofibrosis Care: The Clinical Trial Landscape

Ruchi Desai, MD, is an assistant professor at Virginia Commonwealth University School of Medicine in Richmond. She is also a clinical researcher at the VCU Massey Comprehensive Cancer Center, and her practice and investigative experience span myelofibrosis and other myeloproliferative neoplasms.

Blood Cancers Today spoke with Dr. Desai to hear expert perspective on how myelofibrosis is managed today. In this second interview segment, she speaks about the promising clinical trials underway for treatment of this disease, especially those involving Janus kinase (JAK) inhibitors.

Dr. Desai also identifies which areas in myelofibrosis management require improvement. She cites a need for more options for patients who are ineligible for bone marrow transplant or who require multiple lines of treatment. She explains the limitations of current JAK inhibitors and second-line treatments for myelofibrosis and emphasizes the need for therapies that directly act on the natural history of the disease.